Basic and Diluted Earnings (Loss) per Share - Schedule of the Calculate Net Income (loss) Per Share (Detail) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income (loss) attributable to Thorne HealthTech, Inc.		$ (5,590,705)	$ (88,230)	$ (611,646)	$ 4,618,260
Undistributed earnings (loss) attributable to Series E convertible preferred stockholders		0	(88,230)	0	4,618,260
Numerator for basic earnings (loss) per share-net income (loss) available to Thorne HealthTech, Inc. common stockholders (A)		(5,590,705)	0	(611,646)	0
Undistributed earnings (loss) attributable to Series E convertible preferred stockholders-diluted		0	88,230	0	(4,618,260)
Numerator for diluted earnings (loss) per share-net income (loss) available to Thorne HealthTech, Inc. common stockholders (C)		$ (5,590,705)	$ 0	$ (611,646)	$ 0
Weighted average number of common shares outstanding – basic	[1]	52,731,604	17,650,035	52,648,653	17,650,035
Denominator for basic earnings (loss) per share-weighted average shares (B)	[1]	52,731,604	17,650,035	52,648,653	17,650,035
Denominator for diluted earnings (loss) per share-adjusted weighted average common stock and common stock equivalents (D)	[1]	52,731,604	17,650,035	52,648,653	17,650,035
Basic earnings (loss) per share (A/B)	[1]	$ 0.11	$ 0	$ 0.01	$ 0
Diluted earnings (loss) per share (C/D)	[1]	$ 0.11	$ 0	$ 0.01	$ 0

[1] For the three and six months ended June 30, 2022, 18.1 million and 17.2 million warrants and stock-based awards, respectively, were excluded from the computation of diluted earnings (loss) per share because the effect would have been anti-dilutive under the treasury stock method